Direct oral anticoagulants (DOACs)

被引：8

作者：

Vazquez, Sara ^{[1
]}

Rondina, Matthew T. ^{[2
,3
,4
]}

机构：

[1] Univ Utah, Hlth Sci Ctr, Univ Healthcare Thrombosis Serv, Salt Lake City, UT USA

[2] Univ Utah, Dept Internal Med, Div Gen Internal Med, Salt Lake City, UT 84112 USA

[3] Univ Utah, Sch Med, Program Mol Med, Salt Lake City, UT USA

[4] George E Wahlen Salt Lake City VAMC, Dept Internal Med, Salt Lake City, UT USA

来源：

VASCULAR MEDICINE | 2015年 / 20卷 / 06期

关键词：

anticoagulants; apixaban; dabigatran; edoxaban; rivaroxaban; thrombosis; DVT; pulmonary embolism; PATIENT;

D O I：

10.1177/1358863X15600256

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

DOACs are a new group of blood-thinner medications that may have some advantages over warfarin. A health care provider will look at several different factors to help patients decide if a DOAC is a good choice. Patients taking DOACs should discuss medication changes, a plan for taking the DOAC before and after a surgery, and any bleeding side effects with their health care provider.

引用

下载

页码：575 / 577

页数：3

共 50 条

[31] Direct oral anticoagulants (DOACs) - dabigatran, rivaroxaban, apixaban, edoxaban - addition - EML
SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 339 - 355
[32] Update on Direct Oral AntiCoagulants (DOACs) Perioperative "switching", drug interactions and persistence
Koscielny, Juergen
Rosenthal, Christoph
von Heymann, Christian
HAMOSTASEOLOGIE, 2017, 37 (04): : 267 - 275
[33] Efficacy and safety of direct oral anticoagulants (DOACs) for the secondary stroke prevention in atrial fibrillation
Sakiyama, Y.
Sanayama, H.
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 988 - 988
[34] What is the best time sampling for the two direct oral anticoagulants (DOACs), dabigatran and rivaroxaban?
Douxfils, J.
Baudar, J.
Devalet, B.
Samama, M. M.
Chatelain, B.
Dogne, J-M
Mullier, F.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 9 - 10
[35] Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations
van Es, Nick
Buller, Harry R.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 125 - 131
[36] Ten things ICU specialists need to know about direct oral anticoagulants (DOACs)
Stensballe, Jakob
Moller, Morten Hylander
INTENSIVE CARE MEDICINE, 2019, 45 (01) : 89 - 92
[37] Point-of-Care Testing of Coagulation in Patients Treated with Direct Oral Anticoagulants (DOACs)
Ebner, M.
Peter, A.
Spencer, C.
Ziemann, U.
Poli, S.
CEREBROVASCULAR DISEASES, 2014, 37 : 659 - 659
[38] Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges
Favaloro, Emmanuel J.
Pasalic, Leonardo
Curnow, Jennifer
Lippi, Giuseppe
CURRENT DRUG METABOLISM, 2017, 18 (07) : 598 - 608
[39] Ten things ICU specialists need to know about direct oral anticoagulants (DOACs)
Jakob Stensballe
Morten Hylander Møller
Intensive Care Medicine, 2019, 45 : 89 - 92
[40] Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase®
Sessa, Maurizio
Mascolo, Annamaria
Callreus, Torbjorn
Capuano, Annalisa
Rossi, Francesco
Andersen, Morten
SCIENTIFIC REPORTS, 2019, 9 (1)

← 1 2 3 4 5 →